| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/13/2003 | WO2003011224A2 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 02/13/2003 | WO2003011221A2 PREPARATION AND USE OF α-KETO PHOSPHONATES |
| 02/13/2003 | WO2003011219A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/13/2003 | WO2003011217A2 Grifola extracts and methods of use thereof |
| 02/13/2003 | WO2003011215A2 Method and system to determine revised dosage |
| 02/13/2003 | WO2003011214A2 Novel methods and formulations for administration of active agents |
| 02/13/2003 | WO2003011211A2 Peg-modified uricase |
| 02/13/2003 | WO2003011106A2 Internal image antibodies for optical imaging and therapy |
| 02/13/2003 | WO2003004016A8 Use of substituted gamma-lactone compounds as medicaments |
| 02/13/2003 | WO2002096948A9 Engineered tetravalent antibodies and methods of use |
| 02/13/2003 | WO2002088328A8 Method for generating highly active human dendritic cells from monocytes |
| 02/13/2003 | WO2002087574A3 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 02/13/2003 | WO2002080849A3 Chemotherapeutic induction of egr-1 promoter activity |
| 02/13/2003 | WO2002078638A3 Morpholino imaging and therapy |
| 02/13/2003 | WO2002074231A3 Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata |
| 02/13/2003 | WO2002072032A3 Compounds and methods for identifying, staging and treating cutaneous t-cell lymphoma |
| 02/13/2003 | WO2002072011A3 Stabilized therapeutic and imaging agents |
| 02/13/2003 | WO2002069907A3 Anti-neovasculature preparations for cancer |
| 02/13/2003 | WO2002068379A3 Novel bifunctional chelating compounds containing hydroxamic acid residues |
| 02/13/2003 | WO2002065992A3 A cell therapy method for the treatment of tumors |
| 02/13/2003 | WO2002062810A3 Linkable sialyl lewis x analogs |
| 02/13/2003 | WO2002060482A3 Perylenequinones for use with immunotherapy agents |
| 02/13/2003 | WO2002051434A3 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 02/13/2003 | WO2002051388A3 Treatment of inoperable tumors by stereotactic injection of microspheres |
| 02/13/2003 | WO2002047604A3 Novel use of chalcone class compounds for inhibiting tumoral mass vascularization |
| 02/13/2003 | WO2002046192A3 Thioether substituted imidazoquinolines |
| 02/13/2003 | WO2002043765A9 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 02/13/2003 | WO2002036580A9 Benzoxazole lpaat- beta inhibitors and uses thereof |
| 02/13/2003 | WO2002034283A3 Vegh inhibitors and their use |
| 02/13/2003 | WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 02/13/2003 | WO2002031115A3 Nucleic acid molecules and polypeptides for immune modulation |
| 02/13/2003 | WO2002009755A3 Apo-2l receptor agonist and cpt-11 synergism |
| 02/13/2003 | WO2002006515A3 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 02/13/2003 | WO2001091791A3 Immune-stimulating bacterial cell wall extracts |
| 02/13/2003 | WO2001085763A3 Chimeric peptide immunogens their preparation and use |
| 02/13/2003 | WO2001077107A8 Oxazole derivatives and their uses as tyrosine kinase inhibitors |
| 02/13/2003 | WO2001070772A3 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid |
| 02/13/2003 | US20030032995 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/13/2003 | US20030032827 Lipoxin compounds and their use in treating cell proliferative disorders |
| 02/13/2003 | US20030032804 Methods of treating periodontal disease |
| 02/13/2003 | US20030032803 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase |
| 02/13/2003 | US20030032799 For cancer treatment |
| 02/13/2003 | US20030032791 Nucleotide sequences coding polypeptide for use in the treatment of metabolic, reproductive and eating disorders |
| 02/13/2003 | US20030032775 Effector proteins of rapamycin |
| 02/13/2003 | US20030032664 Method of cancer treatment |
| 02/13/2003 | US20030032663 Inhibition of the interaction of RAGE with its ligands; treatment acute and chronic inflammation, the development of diabetic late complications, Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis. |
| 02/13/2003 | US20030032656 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 02/13/2003 | US20030032654 Useful for the treatment or prevention of asthma and other allergic diseases. |
| 02/13/2003 | US20030032653 Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production |
| 02/13/2003 | US20030032652 Hydroxamic and carboxylic acid derivatives |
| 02/13/2003 | US20030032642 Treating psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD. |
| 02/13/2003 | US20030032641 Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors |
| 02/13/2003 | US20030032633 Use of the active fraction (-)- Olivil as an antioxidant or free radical scavenger. |
| 02/13/2003 | US20030032630 Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kappaB |
| 02/13/2003 | US20030032626 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| 02/13/2003 | US20030032617 Administering nicotinamide, a nicotinamide agonist, a nicotinamide derivative, a nicotinamide metabolite or prodrugs thereof. |
| 02/13/2003 | US20030032610 Administering one or more oligonucleotides which share at least 50% nucleotide sequence identity with (TTAGGG)n or oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. |
| 02/13/2003 | US20030032593 Transporters comprising spaced arginine moieties |
| 02/13/2003 | US20030032584 Inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal. |
| 02/13/2003 | US20030032581 Pharmaceuticals for treating obesity |
| 02/13/2003 | US20030032184 Hepatocyte culture for use monitoring liver metabolism and diagnosing liver disorders |
| 02/13/2003 | US20030032183 Induction of preferential stem cell differentiation; obtain nutrient broths, inoculate with cells, mix with modulator, propagate and recover cells |
| 02/13/2003 | US20030032166 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 02/13/2003 | US20030032097 DNA encoding human vanilloid receptor VR3 |
| 02/13/2003 | US20030032095 Novel nucleic acid sequences encoding human semaphorin-like polypeptides |
| 02/13/2003 | US20030032073 Method for diagnosis and therapy of Hodgkin's lymphomas |
| 02/13/2003 | US20030032050 Methods and compositions using peptide-pulsed dendritic cells for stimulating cytotoxic T lymphocytes specific for tumor cells or virus-infected cells |
| 02/13/2003 | US20030031738 Saponin mixtures and compounds are isolated from the species Acacia victoriae; e.g., glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents |
| 02/13/2003 | US20030031733 Pharmaceutical composition for increasing the production of nitric oxide and IFN-gamma, and process for preparation thereof |
| 02/13/2003 | US20030031704 Liposome composition for delivery of nucleic acid |
| 02/13/2003 | US20030031679 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 02/13/2003 | US20030031673 Treatment and diagnosis of cancer |
| 02/13/2003 | US20030031670 Diagnosis and treatment of malignant neoplasms |
| 02/13/2003 | US20030031669 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 02/13/2003 | US20030031665 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 |
| 02/13/2003 | US20030031627 For diagnosis and therapy |
| 02/13/2003 | US20030029086 Floral packaging material having great masters prints thereon |
| 02/13/2003 | CA2838062A1 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 02/13/2003 | CA2753329A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 02/13/2003 | CA2494304A1 Materials and methods relating to improved vaccination strategies |
| 02/13/2003 | CA2493888A1 Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
| 02/13/2003 | CA2456196A1 Compositions and methods for modulation of immune responses |
| 02/13/2003 | CA2456192A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | CA2456187A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | CA2456177A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 02/13/2003 | CA2456173A1 Quinoline derivatives and use thereof as antitumor agents |
| 02/13/2003 | CA2456092A1 Osteogenic growth oligopeptides as stimulants of hematopoiesis |
| 02/13/2003 | CA2456003A1 Regulator of calcineurin |
| 02/13/2003 | CA2455856A1 Targeted polymeric delivery systems |
| 02/13/2003 | CA2455833A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | CA2455772A1 Substituted isoindoles and their use |
| 02/13/2003 | CA2455598A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | CA2455597A1 Liposomes prepared from the extractable lipids from a mycobacterium |
| 02/13/2003 | CA2455567A1 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 02/13/2003 | CA2455547A1 Use of vitamin e succinate and antiandrogen combination |
| 02/13/2003 | CA2455365A1 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 02/13/2003 | CA2455235A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 02/13/2003 | CA2455194A1 Vascular endothelial growth factor isoform having anti-angiogenic activity |
| 02/13/2003 | CA2455179A1 Androgen receptor modulators and methods of use thereof |
| 02/13/2003 | CA2455154A1 Receptor, the use thereof, and mouse antibodies |